Favrille Ends Specifid Follicular B-Cell NHL Vaccine Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Specifid is the second vaccine candidate for follicular non-Hodgkin’s lymphoma to fail this year, following Genitope’s MyVax results in March.
You may also be interested in...
Genitope Pulls Plug On Cancer Vaccine
FDA wants another Phase III trial with non-Hodgkins lymphoma drug.
Favrille’s Acquisition Of Diversa CD20 Antibodies Bolsters Lead Lymphoma Program
Another firm developing a therapeutic vaccine for lymphoma, Biovest, says it hopes to launch its BiovaxID product in mid-2009.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.